ILMN
A solid quarter, not a sleepy one
Illumina just served up second-quarter fiscal 2026 results, and the headline was pretty friendly: revenue hit $1.16 billion, up 9.5% from a year ago. Strip out currency, acquisitions, and China, and organic growth still clocked in at 8.1% — which is the kind of number that makes investors sit up a little straighter in their chairs.
The margin story matters too
This wasn’t just a top-line flex. GAAP operating margin came in at 21.1%, while non-GAAP operating margin was 22.5%. In other words, Illumina wasn’t just selling more stuff — it was doing it without turning the profit machine into a science fair volcano.
Why you should care
For a company like Illumina, steady revenue growth plus healthy margins is the whole ballgame. Investors tend to watch whether demand for sequencing products is real, durable, and profitable, not just a one-quarter sugar rush. EPS also came in at $1.35 on a GAAP basis and $1.31 non-GAAP, giving the quarter a little extra shine.
Big picture: if you’ve been waiting for proof that Illumina can keep growing while protecting profitability, this report is basically that receipt.